{"id":102549,"date":"2025-03-17T07:30:00","date_gmt":"2025-03-16T20:30:00","guid":{"rendered":"https:\/\/en.econostrum.info\/au\/?p=102549"},"modified":"2025-03-17T02:55:55","modified_gmt":"2025-03-16T15:55:55","slug":"americas-agreement-australia-disadvantage","status":"publish","type":"post","link":"https:\/\/en.econostrum.info\/au\/americas-agreement-australia-disadvantage\/","title":{"rendered":"How America\u2019s \u2018Agreement\u2019 Left Australia at a Disadvantage"},"content":{"rendered":"\n<p>The<strong> US-Australia Free Trade Agreement (<\/strong><a href=\"https:\/\/www.dfat.gov.au\/trade\/agreements\/in-force\/ausfta\/australia-united-states-fta\" target=\"_blank\" rel=\"noopener\">AUSFTA<\/a>), signed in 2005, was hailed as a milestone in economic cooperation between the two allies. However, nearly two decades on, analysts suggest the agreement primarily benefited the United States while offering limited economic advantages to Australia.<\/p>\n\n\n\n<p>While free trade agreements are intended to reduce barriers and promote mutual economic growth, AUSFTA appears to have entrenched a long-running trade imbalance.&nbsp;<\/p>\n\n\n\n<p>According to research from the Crawford School of Public Policy, the deal distorted trade flows, restricted Australia&#8217;s negotiating power in key sectors, and contributed to America&#8217;s consistent trade surplus with Australia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">A Persistent Trade Imbalance<\/h2>\n\n\n\n<p>Economic data shows that, rather than increasing Australian exports to the US, the agreement coincided with a decline. The year after AUSFTA came into effect, Australian exports to the US dropped, while American imports surged.&nbsp;<\/p>\n\n\n\n<p>This imbalance has persisted, with the International Monetary Fund (IMF) estimating that the deal cost Australia over<strong> $5 billion <\/strong>annually.<\/p>\n\n\n\n<p>According to Shiro Armstrong from the Crawford School of Public Policy, AUSFTA led to trade diversion, meaning <a href=\"https:\/\/en.econostrum.info\/au\/australia-regulator-sues-fiig-securities\/\" data-type=\"post\" data-id=\"102510\">Australia <\/a>reduced trade with lower-cost partners in favour of the US, despite less favourable economic conditions.\u00a0<\/p>\n\n\n\n<p>Over the past two decades, America&#8217;s trade surplus with Australia has remained largely uninterrupted, reinforcing concerns that the deal disproportionately benefited the larger economy.<\/p>\n\n\n\n<p>The agreement also deviated from the prevailing trend of regional trade partnerships at the time. By prioritising a bilateral deal with the US, Australia potentially sacrificed greater economic opportunities that could have emerged from broader Asia-Pacific trade <strong>agreements<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Intellectual Property and Pharmaceutical Costs<\/h2>\n\n\n\n<p>Beyond <a href=\"https:\/\/en.econostrum.info\/au\/us-australia-trade-tensions-rise-albanese\/\" data-type=\"post\" data-id=\"102430\">trade <\/a>imbalances, AUSFTA had significant implications for intellectual property laws and pharmaceutical pricing in Australia.\u00a0<\/p>\n\n\n\n<p>According to the Australian National University, one of the most controversial aspects of the agreement was the extension of copyright protections, which aligned Australia&#8217;s laws with US standards, delaying the entry of cheaper generic alternatives.<\/p>\n\n\n\n<p>More critically, AUSFTA altered the <strong>Pharmaceutical Benefits Scheme <\/strong>(PBS), which had long enabled Australia to regulate medicine prices effectively. <\/p>\n\n\n\n<p>Under US pressure, the system was modified to introduce a two-tiered structure, weakening Australia&#8217;s ability to negotiate drug prices. As a result, American pharmaceutical companies gained greater leverage, leading to higher costs for certain medications.<\/p>\n\n\n\n<p>Critics argue that these intellectual property and healthcare provisions illustrate how AUSFTA served US corporate interests while limiting Australia\u2019s ability to maintain independent pricing policies.&nbsp;<\/p>\n\n\n\n<p>According to <strong>Thomas Faunce<\/strong> of the Australian National University, the Pharmaceutical Benefits Scheme (<a href=\"https:\/\/www.pbs.gov.au\/pbs\/home\" target=\"_blank\" rel=\"noopener\">PBS<\/a>) was altered under US pressure, introducing a two-tiered system that weakened Australia&#8217;s ability to negotiate drug prices.\u00a0<\/p>\n\n\n\n<p>This change limited Australia&#8217;s buying and pricing power with US pharmaceutical companies, leading to shortages of lower-priced generic drugs as big pharmaceutical firms pushed their branded, higher-margin products.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The 2005 US-Australia Free Trade Agreement promised economic growth for both countries, but its outcomes tell a different story. While Australia was expected to benefit, it quickly became clear that the deal largely favoured the US. With America&#8217;s trade surplus growing, Australian consumers have felt the impact of higher costs, particularly in healthcare. <\/p>\n","protected":false},"author":10,"featured_media":102551,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-102549","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-economy","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33","no-featured-image-padding"],"_links":{"self":[{"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/posts\/102549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/comments?post=102549"}],"version-history":[{"count":2,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/posts\/102549\/revisions"}],"predecessor-version":[{"id":102552,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/posts\/102549\/revisions\/102552"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/media\/102551"}],"wp:attachment":[{"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/media?parent=102549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/categories?post=102549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/tags?post=102549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}